New Data Show Lilly's Evista® Significantly Reduces Spinal Fractures With Two
Years of Therapy
Medical Meeting To Highlight Results From the MORE Study
Eli Lilly and Company's Evista® (raloxifene hydrochloride), the newest osteoporosis preventive, significantly reduced by about half the risk of new spinal fractures among postmenopausal women after two years of treatment, according to data presented today. These interim data were reported by Bruce Ettinger, M.D., senior investigator, division of research, Kaiser Permanente Medical Care Program, at the annual meeting of the European Congress on Osteoporosis in Berlin, Germany.
"These data are the first to show that a selective estrogen receptor modulator can significantly reduce the risk of spinal fracture," said August M. Watanabe, M.D., Lilly executive vice president, science and technology. "The results from this interim analysis provide further support that Evista protects a woman's bones and may address other health concerns important after menopause."
Two-year results from osteoporosis treatment studies
Ettinger's report analyzes 7,705 postmenopausal women enrolled in the ongoing Multiple Outcomes of Raloxifene Evaluation (MORE) study, a double-blind, placebo-controlled, randomized clinical trial designed primarily to evaluate the effect of daily Evista therapy on bone mineral density (BMD) and spinal fractures in women who have osteoporosis.
Women in the MORE study were on average 66 and one-half years old upon entry
into the trial and have osteoporosis. The two-year analysis demonstrates that
women taking Evista who had no spinal fractures upon entry into the study were
52 percent less likely to have a first spinal fracture and women with a previous
spinal fracture were 38 percent less likely to have new spinal fractures when
compared with their counterparts taking placebo supp
Contact: Laura Miller
Eli Lilly and Company